Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
4A
|
pubmed:dateCreated |
1997-8-13
|
pubmed:abstractText |
The in vitro anti-Helicobacter pylori (H. pylori) activity of ebrotidine (N-[(E)-[[2-[[[2-[(diaminomethylene) amino]-4-thiazolyl]methyl]thio]ethyl]amino]methylene]-4-bromo- benzenesulfonamide, CAS 100981-43-9, FI-3542) versus ranitidine, and their effect on the susceptibility to the antimicrobial agents used in H. pylori eradication were investigated. Assessment was performed by determining the minimum inhibitory concentrations (MIC) against 9 strains of H. pylori, 8 from clinical source and 1 from the American Type Culture Collection (ATCC 43504), in Mueller-Hinton solid media plus 7% blood. The concentration of inocula was 10(7) CFU/ml, incubation was performed at 37 degrees C in microaerophilic atmosphere, and results were read after 5 days of growth. Ebrotidine gave a mean MIC value of 75 micrograms/ml, while that for ranitidine was > 1000 micrograms/ml. Ebrotidine at 100 micrograms/ml enhanced the activity of the antimicrobials studied as follows: erythromycin 3 times, tetracycline 1.1 times, amoxicillin 3 times, metronidazole-sensitive strains 9 times and clarithromycin 5 times. Ranitidine had no effect on the MIC of the antibiotics even at 500 micrograms/ml.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Amoxicillin,
http://linkedlifedata.com/resource/pubmed/chemical/Benzenesulfonates,
http://linkedlifedata.com/resource/pubmed/chemical/Clarithromycin,
http://linkedlifedata.com/resource/pubmed/chemical/Erythromycin,
http://linkedlifedata.com/resource/pubmed/chemical/Histamine H2 Antagonists,
http://linkedlifedata.com/resource/pubmed/chemical/Metronidazole,
http://linkedlifedata.com/resource/pubmed/chemical/Ranitidine,
http://linkedlifedata.com/resource/pubmed/chemical/Tetracycline,
http://linkedlifedata.com/resource/pubmed/chemical/Thiazoles,
http://linkedlifedata.com/resource/pubmed/chemical/ebrotidine
|
pubmed:status |
MEDLINE
|
pubmed:month |
Apr
|
pubmed:issn |
0004-4172
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
47
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
471-4
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:9205746-Amoxicillin,
pubmed-meshheading:9205746-Benzenesulfonates,
pubmed-meshheading:9205746-Clarithromycin,
pubmed-meshheading:9205746-Drug Synergism,
pubmed-meshheading:9205746-Erythromycin,
pubmed-meshheading:9205746-Helicobacter pylori,
pubmed-meshheading:9205746-Histamine H2 Antagonists,
pubmed-meshheading:9205746-Metronidazole,
pubmed-meshheading:9205746-Microbial Sensitivity Tests,
pubmed-meshheading:9205746-Ranitidine,
pubmed-meshheading:9205746-Tetracycline,
pubmed-meshheading:9205746-Thiazoles
|
pubmed:year |
1997
|
pubmed:articleTitle |
In vitro anti-Helicobacter pylori activity of ebrotidine.
|
pubmed:affiliation |
Centro de Investigación Farmacéutica Grupo Ferrer, Barcelona, Spain.
|
pubmed:publicationType |
Journal Article,
Comparative Study
|